Gano Kyle

Gano Kyle, Chief Business Development Officer at Neurocrine Biosciences (NBIX), has demonstrated a clear selling bias in recent insider transactions, with $26.9 million in total sales outweighing $4.9 million in purchases across 44 reported trades. The executive’s activity has been concentrated exclusively in NBIX shares, with six sales since January 2026 accounting for the bulk of the disposals. Notably, on January 16, 2026, Kyle executed two major sales totaling $4.83 million at $240,478 and $4.59 million, accompanied by smaller dispositions earlier that month and in late 2025. The transactions included both open-market sales (code S) and dispositions to satisfy tax obligations (code M), with the latter accounting for $1.31 million in value on January 16 alone. Recent filings show no buys in 2026, continuing a pattern of net reduction in holdings. While some transactions involved minimal or no monetary value—likely representing option exercises or administrative adjustments—the larger sales suggest ongoing monetization of equity. The most recent activity includes multiple dispositions on February 12–13, 2026, totaling $1.32 million, split across transactions of $667,517, $171,906, $150,185, and $325,969. Kyle’s sales have been methodical, with no single trade dominating the trend, but the consistent direction and scale point to a deliberate unwinding of positions over time.